Delaying/reducing the risk of clinical tumour progression after primary curative procedures

European Urology

Volumn 40, Issue SUPPL. 2, 2001, Pages 17-23

  Wirth, M ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Adjuvant therapy; Antiandrogen; Bicalutamide; Immediate therapy; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN;

ADVANCED CANCER; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; GYNECOMASTIA; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO; MASTALGIA; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RISK; WEIGHT GAIN;

EID: 0035742078     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049880     Document Type: Conference Paper

References (23)

1. Cancer statistics, 1999
2. Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: The argument against
3. Quality of life in patients with prostate cancer
4. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up
5. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials
6. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma
7. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men
8. The evolving role of hormone therapy in advanced prostate cancer
9. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer
10. Relationship between tumor size and curability of prostatic cancer by combined chemohormonal therapy in rats
11. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
12. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31
13. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study
14. RTOG Protocol 92-02: A Phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate
15. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors
16. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
17. Study group disease free survival in patients with pathological 'C stage' prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment
18. A review of studies of hormonal adjuvant therapy in prostate cancer
19. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup
20. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer
21. The bicalutamide Early Prostate Cancer Program: Demography
22. Bicalutamide ('Casodex') 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression
23. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement